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Abstract 
Neuromuscular blocking agents are an integral part of anesthesia care, with the inherent 
necessity of reversing its effects prior to patient emergence from anesthesia. 
Sugammadex offers a novel approach to neuromuscular blockade reversal, whose 
mechanism differs from acetylcholinesterase inhibitors traditionally used. However, 
geriatric patients have multiple physiologic age-related changes that can make this 
population at risk to a variety of adverse events during anesthesia care. The purpose of 
this systematic review is to determine if the geriatric population, compared to the adult 
population, requires an altered dose of sugammadex to reduce the incidence of residual 
neuromuscular blockade during the postoperative period. A literature review was 
completed using the databases CINAHL, MEDLINE, and Academic Search Complete on 
Ebscohost. PRISMA framework was used to guide this review. Six studies were 
identified that met inclusion and exclusion criteria. The Critical Appraisal Skills 
Programme checklist was used to systematically assess each study. A data collection 
table was used to organize each study’s methodology and results, with a cross-study 
analysis table to facilitate comparison of included studies. Overall, results showed that 
increased age was associated with increased time to reversal of neuromuscular blockade 
after sugammadex administration. However, there were few adverse events reported and 
a higher incidence of residual neuromuscular blockade and adverse events in the geriatric 
population related to longer recovery time could not be determined using the included 
studies. Further research is needed to determine factors which affect the relationship 
between age and neuromuscular blockade recovery after sugammadex.  
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A Comparison of Neuromuscular Blockade Reversal Using Sugammadex in the Adult 
and Geriatric Population: A Systematic Review 
Background/Statement of the Problem 
Neuromuscular blockade (NMB) agents are integral in anesthesia practice and 
widely used for decades. NMB agents are medications which block skeletal muscle 
movements and are frequently used in surgery to facilitate endotracheal intubation and to 
optimize surgical conditions without relying on higher doses of anesthetic agents which 
may increase risk of adverse reactions (Nagelhout, 2014; Naguib, Lien, & Meistelman, 
2015). Several NMB agents exist in clinical use with varying pharmacokinetic and 
pharmacodynamic properties and the anesthesia provider can choose which is best based 
on intended duration of NMB, patient comorbidities, and goals of anesthesia care.  
Antagonism of the effects of NMB using reversal agents is an essential element of 
anesthesia practice because changes in patient or surgical conditions may require faster 
resolution of NMB, such as NMB effects extending beyond time needed for surgery. 
Incomplete antagonism of NMB continues to be a problem in anesthesia practice, leaving 
patients in a state with partial NMB, also called residual NMB, and potentially exposing 
patients with partially weakened muscle function to complications (Nagelhout, 2014). 
Saager et al. (2019) have found that incidence of residual NMB was observed in nearly 
65% of patients. Adverse events resulting from inadequate antagonism of NMB include 
impaired airway protective reflexes, impaired swallowing, hypoxemia, upper airway 
obstruction, and reduced hypoxic ventilatory drive (Murphy & Brull, 2010). 
Until relatively recently in anesthesia care, antagonism of NMB was primarily 
accomplished by waiting for the NMB agent effect to dissipate and by using 
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acetylcholinesterase inhibitors, such as neostigmine, for NMB antagonism. Sugammadex 
offers a different mechanism of action that avoids potential complications and limitations 
of using acetylcholinesterase inhibitors. Sugammadex is a newer agent for the 
antagonism of neuromuscular blockade and has the advantage of rapid reversal of deep 
levels of neuromuscular blockade (Chingmuh et al., 2009). As the geriatric population 
increases and their health care and surgical needs increase, review of sugammadex 
efficacy to reverse NMB in geriatric patients as a unique population is needed.  
The purpose of this systematic review was to determine if the geriatric population, 
compared to the adult population, requires an altered dose of sugammadex to reduce the 
incidence of residual neuromuscular blockade during the postoperative period. A 
systematic review was conducted to further examine the topic of sugammadex use in 
geriatric surgical patients to reduce incidences of residual neuromuscular blockade 
compared to the adult, to ensure safe and effective use in geriatric patients to reverse 
NMB. The research question to guide this systematic review was: What is the 
relationship of sugammadex dosing in the geriatric population compared with the adult 
population in preventing the incidence of residual NMB in the postoperative period?  
Next, a review of literature will be presented. 
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Literature Review 
 A review of the literature was completed on Ebscohost using the databases 
CINAHL, MEDLINE, and Academic Search Complete. Search terms used include: 
sugammadex, elder*, geriatric, aged, neuromuscular block*, NMB. Articles were limited 
to English language. No date limit was imposed on search results. 
Neuromuscular Junction Physiology 
 The interface between efferent motor neurons and skeletal muscles is called the 
neuromuscular junction. Despite this junction being one of the most studied areas of 
nervous system, complete understanding of its workings is not known (Jeevendra Martyn, 
2015). The axon terminal branches out as it reaches toward the skeletal muscle fiber cell 
membrane. The axon terminal branches of the motor neuron do not contact the muscle 
fiber cell membrane, leaving a junctional space or cleft. Within the axon terminal of the 
motor neuron, acetylcholine is synthesized and stored in vesicles in preparation for 
release into the junctional space. Once an electrical signal (action potential) travels to the 
axon terminal endings, the electrical signal of the nervous system is converted into a 
chemical signal, in the form of acetylcholine release into the junctional space. The action 
potential activates calcium ion channels at the axon terminal, allowing an influx of 
calcium ions into the axon terminal, where vesicles storing acetylcholine await. Calcium 
ion influx allows for the complex interaction of several proteins which ultimately allow 
vesicles to migrate to the axon terminal releasing zones and then exocytosis of 
acetylcholine into the junctional space (Jeevendra Martyn, 2015). 
 Once released into the junctional space, acetylcholine diffuses toward the skeletal 
muscle fiber cell membrane and nicotinic acetylcholine receptors (nAChR). There are 
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several varieties of nAChRs, but in adults without neuromuscular disease the 
predominate nAChR is composed of five subunits: two alpha, one beta, one delta, and 
one epsilon (Jeevendra Martyn, 2015). Both alpha subunits must have an acetylcholine 
molecule bound to activate the nAChR, allowing the influx of predominantly sodium ions 
but also calcium ions into the muscle fiber sarcoplasm and the efflux of potassium ions 
out to the junctional space. If enough nAChRs are stimulated by acetylcholine, the 
electrical gradient of the muscle fiber membrane can reach threshold and produce an end-
plate potential. The end-plate potential will propagate into the muscle fiber via transverse 
tubules to ultimately produce a muscle contraction.  
Neuromuscular Blockade 
 Pharmacologic agents are available that establish neuromuscular blockade 
(NMB), which is the interference with physiologic processes at the neuromuscular 
junction and inhibition of muscular contraction. The primary site of action that enables 
NMB is the alpha subunit of nAChRs. Skeletal muscles are all susceptible to the effects 
of NMB but not all skeletal muscles are equally affected.  
 Variability of blood flow and sensitivity of different muscle groups produces 
patterned responses during onset and recovery of NMB (Nagelhout, 2014). During onset 
of NMB, extraocular movement muscles and extremities are affected first, followed by 
muscles in the neck, chest, abdomen, and lastly diaphragm. During recovery, this pattern 
is reversed, with diaphragm recovering first and extremities and eyes muscles recovering 
last. For this reason, measuring the onset of NMB is best done using a facial nerve, 
commonly observing for stimulation of the orbicularis oculi. Blood flow and drug 
distribution to facial muscles more closely mirrors that of larynx and diaphragm, thus 
5 
 
more closely measures onset of muscle relaxation desired prior to intubation. Measuring 
recovery from NMB is best measured in the periphery, commonly ulnar nerve stimulation 
eliciting a contractile response of the adductor pollicis (adduction of the thumb). If 
adequate recovery can be measured in the more sensitive extremities, then recovery of the 
less sensitive larynx and diaphragm is better ensured. A prospective observational study 
of 150 subjects by Thilen et al. (2012) found an increased incidence of residual NMB 
effects in postanesthesia care unit (PACU) when the orbicularis oculi site was used to 
determine NMB recovery compared to using the adductor pollicis (n=51/99 vs n=11/51, 
respectively, p<0.01). 
Neuromuscular Blockade Agents 
 NMB agents inhibit muscle contraction by interfering with the physiologic 
process occurring in the neuromuscular junction, resulting in the inability for muscles to 
contract and produce movement. There are several drugs clinically available and are 
divided into different categories: depolarizing agents and nondepolarizing agents. It is the 
nondepolarizing agents that will be reviewed in detail, as the depolarizing agents will 
have no bearing on the focus of this systematic review. 
Nondepolarizing agents. Nondepolarizing agents can be divided into two classes 
according to their molecular structure: steroidal and benzoisoquinoliniums. Rocuronium, 
vecuronium, and pancuronium are examples of steroidal nondepolarizing agents. 
Steroidal nondepolarizing agents all have a characteristic structure of four hydrocarbon 
rings that is similar to cholesterol and other endogenous steroids, such as androgens and 
corticosteroids. Benzoisoquinoliniums have a different molecular structure which does 
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not have a steroidal ring structure. Atracurium and cisatracurium are examples of 
benzoisoquinoliniums (Naguib, 2015). 
All nondepolarizing agents are competitive antagonists with acetylcholine, 
binding to an alpha subunit of the nAChR and blocking acetylcholine action at the alpha 
subunit receptor site. Nondepolarizing agents need only to block one alpha subunit to 
prevent activation of the nAChR by acetylcholine. By blocking the alpha subunit of the 
nAChR, nondepolarizing agents do not allow adequate depolarization of the muscle fiber 
cell membrane to reach threshold and produce an end-plate potential needed for initiating 
muscle contraction. As concentration of nondepolarizing agent in the blood plasma 
decreases due to drug metabolism, clearance, and excretion, a concentration gradient 
causes nondepolarizing agent to diffuse from the neuromuscular junction to the plasma. 
As concentration of nondepolarizing agent decreases within the neuromuscular junction, 
acetylcholine then increasingly predominates, and neuromuscular junction physiology 
increasingly returns to normal (Naguib, 2015).  
Neuromuscular Blockade Reversal Agents 
Reversal of NMB effects is an important part of anesthesia clinical practice. NMB 
duration and surgical times do not necessarily coincide. Ongoing NMB into the 
postoperative period can impair protective airway reflexes if not appropriately reversed. 
Also, patients should not experience awareness while immobile from the effects of NMB, 
as this can be psychologically distressful.  
Multiple medications are available to antagonize the effects of nondepolarizing 
agents. Acetylcholinesterase inhibitors includes drugs such as neostigmine and 
edrophonium to inhibit acetylcholinesterase from breaking down acetylcholine, thus 
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increasing the concentration of acetylcholine at the neuromuscular junction (Murphy, De 
Boer, Eriksson, & Miller, 2015). The increased concentration of acetylcholine can 
compete with nondepolarizing drugs at the active site on nAChRs. However, 
acetylcholinesterase is inhibited not just at nAChRs but also at other locations in the 
nervous system, such as muscarinic acetylcholine receptors (mAChRs). Stimulation of 
mAChRs at sites such as the heart and lungs can produce undesirable effects such as 
bradycardia, bradyarrhythmia, and bronchoconstriction. Anticholinergic drugs such as 
atropine and glycopyrrolate are administered with acetylcholinesterase inhibitors to 
counter the effects of increased acetylcholine at mAChR. Sugammadex is not an 
acetylcholinesterase inhibitor, offering a different approach to NMB antagonism that 
avoids potential complications involving acetylcholinesterase inhibitors. 
Sugammadex. Sugammadex, classed as a selective relaxant binding agent, offers 
a new approach to NMB antagonism without affecting acetylcholinesterase (Murphy, De 
Boer, et al., 2015). Sugammadex is made of eight dextrose units in a circular or donut 
shaped configuration. Hydrophobic functional groups are configured toward the hollow 
center of the donut configuration, allowing for binding of hydrophobic compounds. The 
outer portion of the donut configuration is hydrophilic, increasing its water solubility. 
Sugammadex is a modified version of this ring of eight dextrose units to enhance 
electrostatic binding and to physically accommodate the steroidal nondepolarizing drug. 
Of all the NMB agents, sugammadex is only capable of interacting with the steroidal 
class of nondepolarizing agents. The steroidal nondepolarizing drug is bound within the 
dextrose ring structure of sugammadex and reduces the concentration of free steroidal 
nondepolarizing drug available in the plasma. As more drug is bound by sugammadex, a 
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concentration gradient is created, facilitating diffusion of nondepolarizing drug away 
from the neuromuscular junction and toward the plasma, where additional sugammadex 
can bind more nondepolarizing drug. The complex of sugammadex and bound 
nondepolarizing drug is primarily eliminated from the body in urine.  
Unlike acetylcholinesterase inhibitors, sugammadex can reverse deep states of 
NMB. In a randomized clinical trial by Chingmuh et al. (2009), the reversal of 
1.2 mg·kg-1 rocuronium with 16 mg·kg-1 sugammadex was compared to spontaneous 
recovery after 1 mg·kg-1 of succinylcholine, a short-acting depolarizing NMB agent. 
Results from 108 subjects was provided and showed faster recovery (p<0.001) with the 
sugammadex group (mean time 6.2 minutes) compared to succinylcholine (mean time 
10.9 minutes). Mean times of the sugammadex group start from time of rocuronium 
administration. If timed from sugammadex administration, mean time until recovery is 
2.9 minutes. 
Sugammadex does not bind with equal affinity to all drugs. A study by Zwiers, 
van den Heuvel, Smeets, and Rutherford (2011) used isothermal titration calorimetry to 
investigate the binding affinity of sugammadex with over 300 medications. Rocuronium 
has the highest association constant (1.79·107) of all drugs tested, nearly three times 
higher than vecuronium (5.72·106), the drug with second highest association constant. 
Pancuronium also has binding affinity for sugammadex, but approximately half that of 
vecuronium (2.62·106). However, it is important to note that the interaction of 
sugammadex and pancuronium does not result in significant NMB reversal (Murphy, De 
Boer, et al., 2015). Zwiers et al. calculated that fusidic acid, floxacillin, and toremifene (a 
selective estrogen receptor modifier) theoretically can displace rocuronium and delay 
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reversal of NMB. However, no evidence of any clinically significant effect on NMB 
reversal was noted. In prescribing information released by the manufacturer Merck, 
Sharpe, and Dohme Corp (2018), in vitro studies suggest binding affinity of sugammadex 
and progesterone, possibly leading to reduced progesterone levels. No clinically 
significant effect on effectiveness of NMB reversal was stated with this interaction.  
Effective dose ranges have been suggested for a variety of NMB depths by 
Naguib (2015). Effective doses range from 2 mg·kg-1 to 16 mg·kg-1. Lower doses 
(2mg·kg-1 and 4 mg·kg-1) are used for patients with partial spontaneous recovery from 
NMB. Larger doses (8-16 mg·kg-1) are used for more profound NMB, when patients have 
little or no measurable recovery from NMB. Effective doses for obese patients continue 
to be investigated. A prospective observational study found sugammadex doses based on 
ideal body weight insufficiently antagonized NMB in 39.5% (17/43) and 23.4% (18/77) 
of obese patients in deep and moderate NMB block, respectively (Lauradó et al., 2012). 
Van Lancker et al. (2011) found that moderate NMB can be antagonized using a 
sugammadex dose based on ideal body weight +40%. Sugammadex dose calculation 
based on ideal body weight in obese patients could risk insufficient NMB antagonism and 
risk relapse of NMB effect due to insufficient dosing (Murphy, De Boer, et al., 2015). 
 Effective dose was also investigated in those with severe renal impairment. Renal 
excretion is the primary elimination route for sugammadex. Despite rocuronium having a 
primarily biliary excretion route, rocuronium will primarily be excreted in urine once 
bound to sugammadex. Consequently, patients with severe renal impairment present with 
a unique situation. Panhuizen et al. (2015) investigated the reversal of deep NMB using 
sugammadex 4 mg·kg-1 in patients with severe renal impairment who received 
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rocuronium 0.6 mg·kg-1 with subsequent doses of 0.1-0.2 mg·kg-1 to maintain NMB. 
Thirty-five patients with creatinine clearance below 30ml/min were compared to 35 
patients with creatinine clearance above 80ml/min as a control group. From time of 
sugammadex administration in the renal impairment group, time to achieve adequate 
recovery was 3.1 minutes. In the control group, time to achieve adequate recovery was 
1.9 minutes. The renal impairment group showed statistically significant slower recovery 
times (p=0.0002). Although recovery times were prolonged by 1-2 minutes, all renal 
impairment patients achieved adequate recovery following sugammadex administration. 
During follow-up after sugammadex administration, six subjects in the renal impairment 
group continued to have detectable levels of rocuronium in plasma, bound to 
sugammadex, after seven days. Despite effective NMB recovery, there is not enough 
information to recommend routine sugammadex use in patients with creatinine clearance 
less than 30 ml/min due to the potential prolonged exposure to sugammadex-rocuronium 
complex and the potential risk such exposure could entail. Twelve patients did receive 
hemodialysis during this study, but variations in hemodialysis protocols among involved 
facilities did not allow for evaluation of hemodialysis effectiveness in removing 
sugammadex-rocuronium complex in this study. 
Measuring Neuromuscular Blockade  
 Several methods have been employed by anesthesia providers for monitoring 
NMB for the purpose of determining adequate NMB recovery. Physical assessment or 
clinical bedside testing, qualitative measurement using a peripheral nerve stimulator 
(PNS) to assess train of four (ToF), and quantitative measurement devices to measure 
train of four ratio (ToFR) are all examples of NMB monitoring methods.  
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 Quantitative measurement. Quantitative measurement is a type of objective 
measurement using a device to measure NMB and numerically displays the ToFR for the 
user. ToF is the delivery of four consecutive electrical stimuli to elicit a muscle twitch 
with each electrical stimulus. The ToFR is the ratio of the quantitative measurement of 
fourth muscle twitch response to the first muscle twitch response during ToF. Full 
complete recovery without any NMB effect is represented as a ToFR equal to one, 
meaning the fourth and first twitches are equal strength. Increasing NMB effect will 
progressively lower the ToFR closer to zero, meaning the fourth twitch is nearing absent 
while the first twitch is still present. If the fourth twitch is absent, then ToFR is not 
measurable. Eventually, as NMB effect further deepens, all muscle twitches during ToF 
progressively fade, with the first twitch being last to fade. Several quantitative devices 
are described in the literature using various mechanisms to measure NMB. 
Mechanomyography (MMG) measures the force of contraction of the adductor pollicis. 
MMG is often referred to as a “gold standard” of quantitative measurement of NMB. 
MMG is no longer commercially available for clinical use and the complex set-up limits 
the use of MMG to research purposes only (Brull & Kopman, 2017; Murphy, 2018; 
Naguib et al., 2018). Electromyography (EMG) measures the electrical response of a 
muscle in proportion to the contraction force. Naguib et al. (2018) state EMG to be an 
alternative gold standard, with EMG values and MMG values largely interchangeable 
with only minor variations. EMG is not commercially available as a portable device for 
clinical use but is available integrated in a limited number of other monitoring systems. 
(Brull & Kopman, 2017; Murphy, 2018; Naguib et al., 2018). Acceleromyography 
(AMG) is a quantitative measuring device used in practice. AMG uses the piezoelectric 
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effect to measure the acceleration of muscle tissue in response to nerve stimulation. AMG 
devices are susceptible to factors which may produce inconsistent measurements that do 
not always allow AMG to be equivalent to the gold standard MMG or EMG (Murphy, 
2018; Naguib et al., 2018). AMG can often measure baseline ToFR values exceeding 1.0, 
leading to a need to computationally convert or “normalize” AMG data values to allow 
comparison to EMG or MMG. To complicate this issue, some AMG devices may only 
display a maximum value of 1.0 regardless of actual value, which may lead to a false 
assumption by the user that the ToFR value is automatically normalized by the AMG 
device to be comparable to MMG or EMG results. More recent AMG devices can 
measure thumb movement in multiple directions to provide more consistent 
measurements, but many of these recent devices have not yet been validated against 
EMG or MMG and increased accuracy has yet to be demonstrated. Hypothermia, a 
constant threat to patients with surgical fields exposed in cold operating suites, may alter 
measurements. Also, the thumb must be freely moveable, which can be a challenge to 
ensure in various surgical positions, where arms may be tucked in or surgical drapes and 
equipment restrict access.  
 Qualitative measurement. Qualitative measurement is a type of subjective 
measurement and involves the use of a PNS to deliver an electric impulse to elicit a 
muscle contraction. The user must interpret the muscle responses for adequate effect or 
recovery of NMB through visual or tactile means. Several patterns of nerve stimulation 
are described by Murphy (2018) when used to monitor NMB effect of nondepolarizing 
agents: ToF, double burst stimulation, tetanic stimulation, and post-tetanic count (PTC). 
ToF is commonly used and involves delivering four consecutive electrical stimuli using 2 
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Hz and the user subjectively compares the first muscle twitch to the fourth muscle twitch, 
visually and tactilely. Increasing fade of the fourth twitch compared to the first twitch 
indicates increasing depth of NMB. Double burst stimulation involves two consecutive 
short tetanic bursts of electrical stimuli using 50 Hz and may facilitate easier comparison 
of the two sequential muscle twitches. Increasing fade of muscle contraction strength 
during the second burst compared to the first burst indicates increasing depth of NMB. 
Tetanic stimulation delivers a sustained electrical impulse of 50 Hz for 5 seconds while 
observing for sustained muscle contraction. Tetanic muscle contraction which fades 
during the duration of stimulus indicates presence of NMB. PTC, used when NMB is 
deep enough to produce no response at all to ToF stimulation, delivers a tetanic 
stimulation of 50 Hz for 5 seconds followed by 10-20 single stimuli. Fewer muscle 
twitches noted in response to these single stimuli corresponds to deeper NMB and longer 
time until ToF response will return. 
 Capron et al. (2006) compared tactile assessment monitoring of one site to a 
control of mechanomyography (MMG) monitoring of the contralateral hand in 32 
patients who received rocuronium and sevoflurane anesthesia. Out of 203 MMG 
measurements of ToFR 0.4-0.9, only 15 qualitative measurements using ToF could detect 
fade (presence of NMB). Using double burst stimulation, fade was detected by providers 
in 111 of 203. Using 50-Hz tetanic stimulation, fade was detected in 9 out of 84 patients 
with ToFR 0.4-0.9.  Capron et al. have shown qualitative monitoring to potentially miss 
many patients who still have continued effects of NMB.  
 Physical assessment. Certain physical assessment findings have been used to 
assess NMB recovery, such as sustained head-lift of five seconds. However, studies in 
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previous decades have demonstrated that physical assessment findings are not sensitive in 
assessing NMB recovery. Kopmann, Yee, and Neuman (1997) found that all ten of their 
volunteer subjects can maintain a head-lift and leg-lift of 5 seconds at all tested levels of 
NMB (ToFR 0.48-0.75). But physical assessment and bedside clinical testing may still 
have value in detecting residual NMB in the PACU, when patients have already 
recovered from anesthesia and are extubated. Unterbuchner et al. (2017) were able to 
develop an algorithm consisting of multiple physical assessment and bedside tests, such 
as head and arm lift, swallow water, and others, to detect residual NMB in a study of 165 
healthy subjects’ assessment results compared to AMG measurements. Results were only 
sensitive for detecting residual NMB with ToFR <0.7 in a non-geriatric population with 
few or no comorbidities. Unterbuchner et al. concluded that use of quantitative 
monitoring devices during anesthesia and before extubation remains a gold standard.   
 Quantitative measurement, when compared with qualitative measurement and 
physical assessment, allows for detection of more patients with ongoing NMB effects 
when assessing for adequate recovery/antagonism. Naguib et al. (2018) states there is no 
consensus on the definition of terms describing the depth of NMB. Naguib et al. in a 
professional statement proposes definitions of various degrees of NMB. Minimal block is 
defined as ToFR 0.4-0.9, while shallow block is ToFR <0.4. Moderate block begins when 
there are more than zero but fewer than four muscle twitch responses during ToF. Deep 
and then complete block begin when ToF produces no muscle response and PTC must 
then be used.  
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Residual Neuromuscular Blockade  
Residual skeletal muscle weakness may persist after administration of reversal 
agents. Kopman, Yee, and Neuman (1997) studied the effects of NMB on ten volunteers 
without comorbidities. After performing control measurements of sustained head lift of 5 
seconds, sustained leg lift of 5 seconds, hand grasp strength measured with a 
dynamometer, and strength to hold onto tongue depressor with mouth, a 5mg·kg-1 bolus 
of nondepolarizing agent mivacurium followed by continuous infusion was given. The 
tests were repeated at predetermined ToFR measurements, and again when ToFR was 
stable between 0.85 and 0.9 following controlled NMB recovery. All 10 volunteers could 
maintain leg-lift of 5 seconds with ToFR 0.50-0.65 and head-lift of 5 seconds at ToFR 
0.48-0.75. Grip strength at ToFR 0.7 was a mean 57% of control strength value (p<0.01), 
and masseter muscle strength allowing retention of tongue depressor recovered at ToFR 
0.86 (range 0.68-0.95). This small study demonstrated that previous methods used to 
determine adequate NMB recovery, such as sustained head lift, could be performed by 
volunteers with a ToFR 0.7. Indeed, some volunteers never lost the ability to sustain head 
or leg lift during the observation period, despite ToFR in some volunteers as low as 0.48. 
Kopman, Yee, and Neuman demonstrated that common subjective physical assessments 
were not sensitive to assess adequate NMB recovery but reported an unexpected result 
that masseter muscle strength to retain a tongue depressor seemed to correlate with more 
complete NMB recovery. Despite the volunteers’ ability to perform many tests at ToFR 
0.7 and to maintain airway without intervention, investigators all agreed that volunteers 
were insufficiently recovered due to a number of other observations, such as inability to 
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sit up without assist, inability to sip water through a straw, diplopia and visual 
disturbance, and general feeling of weakness.  
Eriksson et al. (1997) studied effects of nondepolarizing agent vecuronium on 
pharyngeal constrictor muscle tone, upper esophageal sphincter tone, bolus transit time, 
muscle coordination, and aspiration monitoring in 14 healthy volunteers using 
videomanometry, fluoroscopy, and ToFR measurements at the adductor pollicis. Control 
measurements were done prior to initiating NMB. Esophageal sphincter resting tone had 
statistically significant reduction at ToFR 0.6, 0.7, and 0.8 (p<0.05). Misdirected 
swallowing and aspiration were observed at ToFR 0.6 (n=4/14), ToFR 0.7 (n=3/14), and 
ToFR 0.8 (n=1/14). Aspirations did not penetrate level of vocal cords into the trachea and 
no volunteers demonstrated signs of aspiration such as cough or respiratory discomfort. 
No aspirations were observed at ToFR 0.9. 
 In this investigation by Eriksson et al. (1997), despite the limited sample and 
inability determine any central dysfunction of swallowing, demonstrated incidences of 
aspiration when ToFR was below 0.9. Airway protection and safety is of paramount 
importance in anesthesia care. ToFR greater than 0.9 has demonstrated satisfactory return 
of pharyngeal function and reduced risk of aspiration in the setting of residual NMB. 
 Currently, surgeries are increasingly performed with the expectation of 
discharging patients home the same day. This places increasing importance on surgical 
patients having sufficient recovery from NMB prior to discharge without relying on a 
hospital admission to provide additional time and monitoring. To better ensure complete 
recovery with least risk to adverse events associated with residual NMB, the currently 
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accepted standard of ToFR ≥0.9 for NMB recovery has replaced the previous standard 
(Naguib et al, 2018). 
 Residual neuromuscular blockade incidence and complications. Fourtier et al. 
(2015) conducted a prospective observational study over one year at eight Canadian 
hospitals on adults undergoing open or laparoscopic abdominal surgery expected to last 
less than 4 hours using at least one dose of nondepolarizing agent for intubation or 
maintenance of NMB. An AMG device was used at 10 specific time points starting prior 
to nondepolarizing agent administration and ending with a final measurement upon 
arrival to PACU. Attending anesthesiologist and all nurses were masked to the 
measurements of the AMG device and were not allowed other means of quantitative 
assessment of NMB. Practitioners could provide care using a qualitative device consistent 
with usual practice. No medication doses were standardized and decision to extubate was 
at the discretion of the attending anesthesiologist.  
Data was available for 241 patients at tracheal extubation and 207 patients on 
arrival to PACU. Fourtier et al. found the incidence of residual NMB (defined as 
normalized ToFR <0.9) at time of extubation and on arrival to PACU were 63.5% and 
56.5%, respectively. A positive association was found between incidence of residual 
NMB and higher dose of rocuronium per minute of surgery at time of extubation and at 
time of PACU arrival (p=0.021 and 0.007 respectively). A low incidence of postoperative 
complications did not allow for an assessment of the impact of residual NMB on 
postoperative complications. Three patients were diagnosed with pneumonia or 
atelectasis, one patient required assisted ventilation, and one was reintubated. A 
qualitative device was used in approximately 66% of surgeries, while neostigmine was 
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used for NMB antagonism in approximately 72% of surgeries. The use of neostigmine 
without using a PNS was not associated with reduced incidence of residual NMB at 
extubation and on arrival to PACU (p=0.543 and 0.135, respectively). The use of a PNS 
was associated with reduced incidence of residual NMB at arrival to PACU (p=0.028) but 
not at extubation (p=0.273). Fourtier et al. observed that usual anesthesia practice 
resulted in many patients measuring to have residual NMB, despite use of reversal agent 
neostigmine and a PNS, and brought attention to a need to examine practices in 
anesthesia regarding reducing incidences of residual NMB. Although in this study, 
despite high incidences of residual NMB, a relatively small number of complications 
were reported. 
Saager et al. (2019) conducted a similar year-long, prospective observational 
study at ten hospitals in U.S.A. on 255 adults undergoing open or laparoscopic abdominal 
surgery. An AMG device was used to determine residual NMB, defined as ToFR <0.9. 
Anesthesia providers could provide routine clinical practice using reversal agent and a 
qualitative device at their discretion while masked to AMG results. Residual NMB 
incidence was 64.7% (n=165/255), while 31% (n=79/255) had ToFR as low as <0.6 
despite routine clinical judgment determining suitability for extubation. Shorter surgery 
times, shorter times between administration of NMB agent and extubation, and shorter 
times between administration of reversal agent and extubation were all associated with 
increased incidence of residual NMB (p=0.003, 0.001, and 0.02, respectively). Many 
patients had residual NMB at extubation regardless if providers used neostigmine without 
PNS or in combination with a PNS, 64% (n=52/81) and 65% (112/171) respectively. 
19 
 
Again, low incidence of complications did not allow sufficiently powered statistical 
analysis of residual NMB impact on incidences of complications in this study.  
In a quality improvement project, Murphy et al. (2008) observed high incidences 
of residual NMB in patients with critical respiratory events (CREs) in the first 15 minutes 
of arrival to PACU. Of the 7,459 patients over a one-year period who received general 
anesthesia, 61 developed a CRE and 42 cases were matched with a control for statistical 
analysis. Only one of the 61 patients who experienced a CRE did not receive a NMB 
agent. ToFR <0.7 was measured in 31 of 42 CRE cases. Mean ToFR 0.62 (SD ± 0.2) was 
measured in patients experiencing a CRE, significantly less than control patients (mean 
ToFR 0.98, SD ±0.07, p=<0.0001). Most frequent CRE criterion observed were 
SpO2<90% on 3 liters/minute oxygen via nasal cannula (59.0%), upper airway 
obstruction requiring jaw thrust, oral airway or nasal airway intervention (34.4%), and 
SpO2 90%-93% on 3 liters/minute oxygen via nasal cannula (19.7%). Reintubation 
occurred in 6.2% of CRE events. Multiple CRE criteria was observed in 34.4% of cases. 
None of the control patients displayed any criteria of CRE. Murphy et al. states 
limitations as inability to suggest causal relationship, possible unknown confounding 
variables when determining control group, and long-term consequences of residual NMB 
were not assessed and remain unaccounted. Despite these limitations, this study 
highlights possible adverse outcomes of residual NMB. 
Geriatric Perioperative Considerations  
The geriatric population is a fast-growing segment of the population in many 
countries, requiring increased healthcare needs and resources due to cumulative organ 
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function decline associated with aging. Geriatric persons can have unique risks that 
predispose to perioperative complications when anesthetic care involves NMB agents. 
Cedborg et al. (2014) observed pharyngeal dysfunction in 17 geriatric subjects 
(aged 65 years and older without stated history of dysphagia, diabetes, gastric reflux, or 
surgery to pharynx, larynx or esophagus) using videoradiography and manometry, prior 
to administration of NMB agent and during minimal NMB states with ToFR of 0.7, 0.8, 
and spontaneous recovery to >0.9. A rocuronium drip was used to attain desired steady 
states of NMB measured using an MMG device for a total of 669 swallowing maneuvers, 
with and without contrast. Prior to administering rocuronium, 37% of swallows showed 
at least one criterion for pharyngeal dysfunction. Pharyngeal dysfunction incidence 
increased, compared to control measurement, to 67% (p=0.014) and 71% (p=0.009) at 
ToFR 0.7 and 0.8, respectively. After spontaneous recovery to ToFR >0.9, no statistically 
significant difference was noted in pharyngeal function compared to control (45%, 
p=0.44). No effect was observed in the coordination of breathing and swallowing 
throughout the study. The use of NMB agents was associated with increased pharyngeal 
dysfunction, even at minimal NMB levels in this study. It was also concerning the 
percentage of geriatric subjects with observable criteria for dysphagia, even prior to the 
use of rocuronium and without stated history of dysphagia.  
Flood (2015) describes several geriatric physiologic and pharmacologic 
considerations affecting NMB.  Decreased chest wall compliance reduces effectiveness 
of intercostal breathing muscles and reduces vital capacity, requiring more work by the 
diaphragm and abdominal muscles for breathing. Declining diaphragm function and a 
mechanical disadvantage of a more flattened diaphragm position places the elderly in a 
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more vulnerable situation. Liver function is generally preserved, although protein 
synthesis may be reduced, especially in setting of poor nutrition. Decreased plasma 
proteins that bind drugs and decreased plasma cholinesterase can increase free unbound 
drug to circulate to effect sites. Glomerular filtration rate decreases by 1 mL/min/year 
after 40 years of age, potentially affecting renal clearance of drugs and metabolites. 
Reduced skeletal muscle mass alters drug disposition with redistributed blood flow to 
other body compartments and reduces neuromuscular reserve, potentially exposing 
geriatric patients to increased risk of NMB complications. 
Murphy, Szokol, et al. (2015) conducted a prospective observational cohort study 
comparing the incidence of residual NMB in geriatric individuals (70 to 90 years old) to 
younger adult individuals (18 to 50 years old) groups. Anesthetic care and medications 
were standardized in each cohort. An AMG device was used for ToFR measurement for 
the 300 subjects, 150 subjects in each cohort. A higher incidence of residual NMB (ToFR 
<0.9) was observed in the geriatric cohort (57.7% versus 30.0%, p=<0.001). The geriatric 
cohort was observed to have an increased incidence of airway obstruction during 
transport to PACU (18.58% vs. 7.3%, p=0.003), increased incidence of SpO2 90 to 94% 
in PACU (38.3% vs 17.3%, p=<0.001), and increased incidence of atelectasis or 
pneumonia on chest radiograph during hospitalization (15.4% vs 2%, p=<0.001). No 
statistically significant difference in total rocuronium dose or time from reversal to 
extubation was observed among the cohorts. It is not clear whether the cause of these 
increased incidences is caused by use of NMB agents and reversal agents, normal 
physiologic changes associated with aging, complication of hospitalization, or 
combination of factors.   
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Geriatric population may take several medications for multiple comorbidities, 
increasing the likelihood of possible medication interactions. Naguib (2015) describe 
several medications that can alter the potency of nondepolarizing agents. Antibiotics such 
as aminoglycosides, clindamycin, and tetracycline can enhance NMB effect.  
Antidysrhythmic drug quinidine can also increase potency of nondepolarizing drugs. 
Chronic anticonvulsant therapy can decrease potency, leading to earlier recovery from 
NMB and a need for higher doses to establish adequate NMB. Naguib (2015) also states 
several drugs routinely used by anesthesia providers, such as inhaled anesthetics and 
large doses of locally injected anesthetic, can increase potency of nondepolarizing drugs. 
 Studies and literature reviews have examined sugammadex use in the geriatric 
population, but no systematic reviews were found which methodically examined the 
available evidence. Given the unique risks to the geriatric population, a systematic review 
was conducted to determine if the geriatric population, compared to the adult population, 
requires an altered dose of sugammadex to reduce the incidence of residual 
neuromuscular blockade during the postoperative period. A systematic review was 
conducted to determine what is the relationship of sugammadex dosing in the geriatric 
population compared with the adult population in preventing the incidence of residual 
NMB in the postoperative period. 
Next, the theoretical framework will be presented. 
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Theoretical Framework 
 The Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) is the framework for this systematic review. PRISMA guides the transparent 
and standardized reporting of systematic reviews and assists in the evaluation of 
systematic reviews by other readers (Liberati et al., 2009). PRISMA expanded upon prior 
Quality of Reporting of Meta-analyses (QUOROM) guidelines in response to a growing 
use of systematic reviews of randomized controlled trials to summarize evidence 
(Liberati et al., 2009). QUOROM guidelines also increase standardization and rigor to the 
systematic review process and desire to include systematic reviews with meta-analyses in 
the guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009). While the focus of PRISMA 
is to aid in the reporting of systematic reviews of randomized trials, PRISMA can be used 
for systematic reviews with basis in other research (Moher, Liberati, Tetzlaff, & Altman, 
2009). 
 PRISMA utilizes a checklist and a flow diagram to provide a standardized 
approach to completing and reporting systematic reviews (Moher, Liberati, Tetzlaff, & 
Altman, 2009; PRISMA, 2015). The checklist (Appendix A) contains 27 required 
elements of a systematic review and organized into the categories of title, abstract, 
introduction, methods, results, discussion, and funding. The flow diagram (Figure 1) 
graphically details the process of obtaining studies for a systematic review through four 
phases: Identification, Screening, Eligibility, and Included. The checklist and flow 
diagram were both used to guide the completion of this systematic review using a 
standardized approach. 
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Figure 1. PRISMA 2009 Flow Diagram. From http://www.prisma-statement.org/ 
PRISMAStatement/FlowDiagram 
 
 A Critical Appraisal Skills Programme (CASP) checklist was used to assist with 
systematic evaluation of studies included in the systematic review. The CASP checklist is 
a critical appraisal tool that contains 12 questions to evaluate and identify limitations of a 
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study’s results and assess research integrity and trustworthiness (Critical Appraisal Skills 
Programme, 2018a). The checklist is divided into the following three sections: Are the 
results valid? What are the results? Will the results help locally? (Critical Appraisal Skills 
Programme, 2018b).  
 Next, the methods will be presented. 
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Method 
Purpose 
 The purpose of this systematic review was to determine if the geriatric population, 
compared to the adult population, requires an altered dose to reduce incidences of 
residual neuromuscular blockade during the postoperative period. 
Inclusion/Exclusion Criteria 
 Studies considered for inclusion were those examining sugammadex use in the 
geriatric population and adult population with outcomes regarding residual NMB 
compared between the two populations. Geriatric population was defined as adults aged 
65 years and older. Adult population was defined as those aged 18 years and above but 
less than 65 years. Quantitative measurement data of residual NMB in the postoperative 
period is needed to facilitate comparison between studies. Postoperative period was 
defined as beginning from time of extubation (or from time of entry into PACU or critical 
care unit if not extubated). Included studies must also involve sugammadex for reversal 
of nondepolarizing NMB agent rocuronium. Exclusion criteria included studies primarily 
involving pediatric subjects (less than 18 years old) and studies involving subjects with 
neuromuscular diseases and limitations, such as myasthenia gravis and hemiparesis due 
to cerebral vascular accident. Studies not written in English or without English translation 
were excluded. No date limit was imposed.  
Search Plan 
Databases used on Ebscohost were CINAHL, MEDLINE, and Academic Search 
Complete. Search terms used include: sugammadex, elder*, geriatric, aged, 
neuromuscular block*, NMB. Titles and abstracts were used to screen search results as 
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part of the search strategy. This systematic review considered the inclusion of 
randomized controlled trials. However, no randomized controlled trials that meet the 
inclusion criteria and allowed the comparison of geriatric and adult populations were 
noted. This systematic review then considered prospective non-randomized cohort studies 
for inclusion.  
Critical Appraisal 
 The CASP Cohort Study checklist (2018b) was utilized to systematically appraise 
studies for research integrity and trustworthiness and to assist with identification of any 
limitations that may impact the strength of research results. All studies eligible for 
inclusion was subjected to this appraisal tool. The CASP Cohort Study Checklist was 
chosen for this systematic review as no randomized controlled studies which met 
inclusion criteria were identified at the time of literature search, which necessitated the 
inclusion of prospective nonrandomized studies for systematic review. The CASP Cohort 
Study Checklist is shown below (Table 1).  
Data Collection 
 After critical appraisal, data collection tables were used to organize data regarding 
specific studies included into the systematic review. These tables (Table 2) include 
purpose, sample, site, method, limitations, and results.  
Cross-Study Analysis 
 After critical appraisal and data collection, a cross-study analysis table (Table 3) 
was used to compare pertinent results across all included studies. NMB agent and 
sugammadex dose, time to recovery of ToFR to >0.9 for each age group, and any adverse 
events was included in the cross-study analysis table.   
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Table 1 
CASP Cohort Checklist 
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue?    
2. Was the cohort recruited in an acceptable way?    
3. Was the exposure accurately measured to minimise 
bias? 
   
4. Was the outcome accurately measured to minimise 
bias? 
   
5a. Have the authors identified all important confounding 
factors?  
   
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
   
6a. Was the follow up of the subjects complete enough?    
6b. Was the follow up of subjects long enough?    
Section B. What are the results?    
7. What are the results of this study?  
8. How precise are the results?  
9. Do you believe the results?    
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population?    
11. Do the results of this study fit with other available 
evidence? 
   
12. What are the implications of this study for practice?    
 
Table 2  
Data Collection Table 
Citation 
Purpose Site/Sample Method Results Limitations 
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Table 3 
Cross-Study Analysis 
Study NMB dose Sugammadex 
dose 
Geriatric 
time to 
recovery 
Adult 
Time to 
recovery 
Adverse Events 
      
 
 Next, the results will be discussed. 
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Results 
 A total of 316 articles were identified in the literature search, 30 of which were 
excluded due a pediatric focus. Using the inclusion and exclusion criteria, six studies 
were included for analysis in this systematic review. The PRISMA flow diagram 
illustrating the search results is shown in figure 2. Critical appraisal for each study using 
the CASP checklist is presented in Appendix B. Data collection tables for each included 
study are in Appendix C. Appendix D presents the cross-study analysis for outcomes 
comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PRISMA flow diagram of search results. 
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 The study by Kadoi, Nishida, and Saito (2013) sought to compare the recovery 
times from rocuronium-induced NMB using sugammadex between two groups receiving 
electroconvulsive therapy: young (≤50 years old) and elderly (≥70 years old). This study 
also investigated the existence of a correlation between cardiac index and reversibility of 
rocuronium-induced NMB using sugammadex. Seventeen subjects were recruited (young 
group, n=8; elderly group, n=9) in this prospective observational study. Induction of 
general anesthesia and NMB was standardized in both groups with weight-based dosing 
of propofol and rocuronium. Sugammadex dosing was standardized in both groups also. 
Procedure and location of NMB monitoring was standardized in all subjects. All patients 
were noted to have no response to ToF stimulation at time of sugammadex 
administration, due to short time elapsed since rocuronium administration.  
 The results for this study are shown in Appendix C, Table C-1. All subjects were 
accounted for this study. The young group had a recovery time of 403±37 seconds 
(mean± standard deviation [SD]). The elderly group had a longer recovery time of 
443±36 seconds (mean±SD). This finding was considered statistically significant (P= 
0.04). This study also reported a longer time to loss of ToF response after administration 
of rocuronium in the elderly group, with the young group requiring 102±10 seconds 
(mean±SD) and elderly group requiring 139±32 seconds (mean±SD). A statistically 
significant correlation between cardiac index and onset of NMB was reported (P<0.01) 
but no statistically significant correlation was found between recovery time to ToFR 0.9 
and cardiac index (P= 0.80). No postoperative events related to relapse of NMB or 
respiratory events were reported. Limitations in this study include small sample size and 
a dose of sugammadex larger than typically used in clinical practice. Kadoi, Nishida, and 
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Saito (2013) discussed that recovery times reported in this study were also comparatively 
longer than reported NMB recovery times in other studies after administration of 
sugammadex. This finding was attributed to the timing of sugammadex relatively soon 
after rocuronium administration, when NMB was likely profound with little spontaneous 
recovery. Although 8 mg·kg-1 would be considered appropriate in this study given that 
only a few minutes have elapsed since a large dose of rocuronium, this is different from 
routine clinical scenarios where a smaller dose of sugammadex is often given a 
significant time after rocuronium administration and significant spontaneous recovery of 
NMB may have occurred. Chronic psychiatric illness and its effects on overall physical 
health may have also contributed.  
 The CASP appraisal for this study can be seen in Appendix B, Table B-1. The 
study compared age populations desired for this systematic review. While the results are 
generally congruent with other studies, the sugammadex dose used and timing of 
sugammadex relative to a large dose of rocuronium may limit generalization to typical 
clinical situations outside of electroconvulsive therapy. 
 A multicenter prospective observational study by McDonagh et al. (2011) 
investigated the impact of age on the pharmacokinetics of sugammadex for the reversal 
of rocuronium-induced NMB. Subjects were stratified into three groups: Adult (aged 18-
64 years, n=45), Elderly (aged 65-74 years, n=57), and Old-elderly (aged ≥75 years, 
n=35). All patients were American Society of Anesthesiologists (ASA) Physical Status 1-
3, undergoing elective surgery in supine position requiring general anesthesia and muscle 
relaxation. Rocuronium dose was standardized to 0.6 mg·kg-1 with induction and 
subsequent rocuronium doses of 0.15 mg·kg-1 whenever the ToF stimulation revealed at 
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least two twitches. Sugammadex dose was standardized at 2 mg·kg-1 and given at the end 
of surgery upon reappearance of the second twitch using ToF.  
Results are described in Appendix C, Table C-2. Time from sugammadex 
administration to recovery of ToFR 0.9 was reported. The Adult group had a time of 2.3 
minutes (mean, standard deviation [SD] 1.0 minutes) to recover to ToF 0.9, Elderly group 
with 2.7 minutes (mean, SD 1.4 minutes), and Old-elderly group with reported time of 
3.7 minutes (mean, SD 1.6 minutes). Combined data of Elderly and Old-elderly groups 
(all subjects ≥65 years old) had a reported recovery time of 3.1 minutes (mean, SD 1.6 
minutes). A statistically significant difference was found between the Adult group and 
the combined elderly data group (P=0.017). Thirteen additional subjects had quantitative 
monitoring data that was unavailable or considered unreliable. The above results 
excluded these thirteen subjects. The investigators used data in the 95th percentile to 
incorporate these thirteen subjects and reported these results separately. Overall, results 
were similar, with combined Elderly and Old-elderly groups showing statistically 
significant (P=0.022) longer recovery to ToFR 0.9 than Adult group (3.3 minutes [mean, 
SD 1.7 minutes] versus 2.5 minutes [mean, SD 1.4 minutes], respectively). Investigators 
reported all adverse events and felt that two patients in the Elderly group had adverse 
events that may be related to sugammadex. One patient experienced tachycardia, pyrexia, 
dizziness, and oliguria. Another patient experienced procedural hypotension. Also, one 
patient in the Old-elderly group had reported mild muscle weakness, but recurrence of 
NMB could not be definitively ruled out by investigators as NMB monitoring had ceased 
by that point postoperatively. No respiratory events or reintubations attributed to 
incomplete recovery or relapse of NMB were reported. Limitations include a lack of 
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discussion regarding standardizing inhalational anesthetics to age-adjusted dosages. The 
Old-elderly group (mean age 80.1 years old [SD 4.1 years]) may have received relatively 
more inhalational anesthetic than the adult group (mean age 45.5 years old [SD 11.3 
years]) if age-adjusted dosage was not accounted in this study. 
CASP appraisal for this study is found in Appendix B, Table B-2. Results and aim 
of this study are pertinent to this systematic review. Rocuronium and sugammadex 
dosages more closely resemble clinical use and a larger sample across multiple centers 
improves generalizability of results. However, a lack of discussion regarding 
standardizing and use of age-adjusted dosing of inhalational agents may introduce a 
potential threat to validity. Volatile inhalational anesthetics are known to potentiate NMB 
effect, but it is difficult to estimate its significance in this study without additional 
information such as length of surgery and inhalation dosages used. 
Muramatsu et al. (2018) tested the hypothesis that recovery from deep NMB with 
low dose sugammadex is slower in elderly patients than in nonelderly patients and that 
elderly patients would experience a higher incidence of relapse of NMB. Their 
observational study included 40 subjects (Nonelderly <70 years old [n=20] and Elderly 
≥70 years old [n=20]) undergoing surgery with general anesthesia using only intravenous 
anesthetics propofol and remifentanil infusions. All patients received rocuronium 0.6 
mg·kg-1 after induction and confirmed to have no response to ToF stimulation prior to 
intubation. Spontaneous recovery to ToFR >0.5 was then allowed. Then, rocuronium 0.4 
mg·kg-1 was given with additional doses of 0.2 mg·kg-1 if needed to deepen NMB to a 
PTC range of 2 through 10. Once target NMB attained, sugammadex infusion 50 
mcg/kg/min was initiated until ToF count of 3 achieved. Once ToF count of 3 was 
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achieved, the sugammadex infusion was discontinued. ToFR was measured for at least 30 
minutes after sugammadex infusion was discontinued. The subjects were maintained on 
mechanical ventilation and in general anesthesia using only intravenous anesthetics 
during this period. Once study was completed, additional sugammadex was administered 
prior to emergence and extubation. 
 Results can be found in Appendix C, Table C-3. Spontaneous recovery to ToF 
count of 1 after the initial rocuronium dose was slower in the Elderly group compared to 
Nonelderly group (45.4 minutes and 30.2 minutes, respectively, P=0.016). Recovery time 
to ToF count of 3 after initiation of sugammadex infusion was also slower in the Elderly 
group than the Nonelderly group (15.3 minutes and 11.7 minutes, respectively, P=0.018). 
The investigators also noted two phases of recovery after initiation of sugammadex 
infusion. Early-phase recovery was characterized by a more rapid recovery and increase 
in ToFR soon after initiation of sugammadex infusion. Late-phase then followed, 
characterized by a slower recovery rate of ToFR. No significant difference was noted 
between the two groups during the early-phase recovery (P=0.607). A significant 
difference was noted during late-phase recovery (0.006), with Elderly group having a 
slower rate of recovery than the Nonelderly group. Relapse of NMB, defined in this study 
as a negative change in ToFR after sugammadex infusion was discontinued, was more 
frequent in the Elderly group (n=7, P= 0.044) than the Nonelderly group (n=1).  
 The CASP critical appraisal tool for this study is found in Appendix B, Table B-3. 
This study used total intravenous anesthesia, which removed inhalational anesthetics as a 
possible confounding variable. This study used a sugammadex infusion in the design, 
which is not usual clinical practice. While it served to experimentally replicate situations 
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of low sugammadex dosing, it is not known how accurately this reflects actual clinical 
situations of low sugammadex doses leading to relapse of NMB. No follow-up 
monitoring postoperatively was stated. It is not known if any incidences of NMB relapse 
occurred after the study completed, during recovery in the PACU. Although incidences of 
NMB relapse were not likely due to additional sugammadex given to all subjects at the 
conclusion of the observation period. 
A study by Shin et al. (2016) investigated the dose of sugammadex needed to 
recover from deep NMB within two minutes for the geriatric and adult populations. 
Forty-four subjects, ASA Physical Status 1 or 2, undergoing elective ear nose throat 
surgery under general anesthesia were enrolled. Subjects were separated into two groups: 
Young Adult (n=22, aged 20-40 years) and Elderly Adult (n=22, aged ≥70 years). 
Rocuronium dose with induction was 0.6 mg·kg-1 and maintenance doses of 0.2 mg·kg-1 
used to maintain a PTC of 1 or 2 until the end of surgery. Sugammadex 4 mg·kg-1 was 
given to the first subject and observed if recovery to ToFR ≥0.9 occurred within 2 
minutes. Sugammadex dose for subsequent subjects was increased or decreased by 0.5 
mg·kg-1 depending on the previous subject’s failed or successful rapid recovery to ToFR 
≥0.9 within 2 minutes. Anesthesia providers were masked to the sugammadex dose given 
during the study. The isotonic regression method was used to determine the effective 
dose for 50 percent of subjects (ED50) and 95 percent of subjects (ED95) for the Young 
Adult and Elderly Adult groups. General anesthesia was provided with propofol and 
remifentanil infusions and without the use of inhalational anesthetics.  
 Results are displayed in Appendix C, Table C-4. For the Adult group, ED50 and 
ED95 for sugammadex is 3.3 mg·kg-1 (83% confidence interval [CI], 3.2-3.4) and 4.4 
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mg·kg-1 (95% CI, 3.9-4.5), respectively. The Elderly Adult group ED50 for sugammadex 
is 4.5 mg·kg-1 (83% CI, 4.2-5.0) and ED95 is 5.4 mg·kg-1 (95% CI, 4.9-5.5). Statistical 
significance was determined by non-overlapping CI between the two groups for ED50 and 
ED95. The investigators discussed limitations, which include baseline ToFR values often 
exceeding 1.0. The investigators chose not to normalize the ToFR values for this study 
and instead limited baseline ToFR values to be within 0.95 and 1.05 to minimize the 
potential of overestimation of recovery from NMB. No postoperative events due to 
respiratory complications or NMB relapse were reported in any subjects. 
 CASP appraisal can be found in Appendix B, Table B-4. Overall, results are 
congruent with other studies. Masking the anesthesia provider from the sugammadex 
dose and removing inhalational anesthetics from general anesthesia were efforts to 
improve validity of results by limiting elements of bias and confounding variables. All 
subjects were ASA Physical Status 1 or 2, which help limit excessive comorbidity 
differences between the two groups. This study focused on outcomes and age populations 
desired for this systematic review.  
 Suzuki et al. (2011) investigated the reversibility of profound rocuronium-induced 
NMB using sugammadex in younger and older subjects. Younger subjects (aged 20-50 
years, n=15) and older subjects (aged ≥70 years, n=15) were undergoing gynecological 
surgery under general anesthesia and of ASA Physical Status 1 through 3. All subjects 
received rocuronium 1 mg·kg-1 with subsequent doses of 0.02 mg·kg-1 whenever a PTC 
of 1 or 2 was observed. General anesthesia was maintained using sevoflurane 1%-1.5% 
and remifentanil infusion 0.02-0.05 mcg/kg min. All subjects at the end of surgery were 
given sugammadex 4 mg·kg-1 when spontaneous recovery to PTC of 1 or 2 was observed. 
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Time to recovery of ToFR 0.9 was recorded while sevoflurane and remifentanil were 
continued. Subjects were monitored for 24 hours after surgery for respiratory events. 
 Results can be found in Appendix C, Table C-5. For the younger adult group, 
recovery to ToFR 0.9 after administration of sugammadex was 1.3 minutes (SD 0.3 
minutes, range 0.8-2.0 minutes). The older adult group had a mean recovery time of 3.6 
minutes (SD 0.7, range 2.4-4.5 minutes, P<0.0001). Duration of surgery was significantly 
longer for the older adult group (mean 177.5 minutes, P=0.0015) than the younger adult 
group (mean 118.5 minutes). Total rocuronium dose and weight were similar between the 
younger adult (mean 57.2kg, mean 93.4 mg rocuronium) and older adult (mean 55.9 kg, 
mean 97.5 mg rocuronium) groups. The investigators reported no postoperative events 
attributable to relapse of NMB after reversal with sugammadex. 
 The CASP critical appraisal tool for this study can be found in Appendix B, Table 
B-5. This study contained only female subjects who underwent gynecological surgery, 
which may limit generalizability to other populations. The use of inhalational agent and 
along with longer duration of surgery for the older adult group may prolong the NMB 
effect in the older adult group. ASA physical status 3 subjects may have also introduced 
additional comorbidities to this study, but all subjects were free from neuromuscular, 
renal, and hepatic disease as part of the inclusion criteria. It is unknown from the data 
reported if ASA Physical Status 3 subjects were overrepresented in the older adult group. 
Overall, this study investigated the age groups and outcomes desired for this systematic 
review. 
 An investigation by Yazar et al. (2016) compared the effects of sugammadex on 
the duration of recovery from rocuronium and incidence of NMB relapse between the 
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young elderly (65-74 years old, n=30) and middle-aged elderly (≥75 years old, n=29) 
groups. All subjects were undergoing laparoscopic cholecystectomy and were ASA 
Physical Status 1 through 3. All subjects received rocuronium 0.6 mg·kg-1 with 
subsequent doses of 0.15 mg·kg-1 whenever ToF count of 2 or more was observed. 
General anesthesia was maintained using 50% nitrous and 1.5% sevoflurane (end-tidal 
concentration). Sugammadex 2 mg·kg-1 was given at the end of surgery upon 
spontaneous recovery to ToF count of 2. Recovery time to ToFR 0.9 and incidences of 
ToFR returning to <0.9 after NMB recovery were recorded. Patients were monitored for 
adverse events for 60 minutes postoperatively while ToFR was reassessed 5 minutes into 
the postoperative period to evaluate for relapse of NMB effect. 
 Results can also be found in Appendix C, Table C-6. The middle-aged elderly 
group had a longer recovery time to ToFR 0.9 than the young elderly group (mean 5.5 
minutes [range 2.47-9.54 minutes] versus mean 3.27 minutes [range 1.41-5.37 minutes, 
P<0.001], respectively). Yazar et al. reported no significant difference between the two 
groups regarding gender, ASA Physical Status, BMI, duration of surgery, duration of 
anesthesia, and total amount of rocuronium used in surgery. Time for rocuronium to 
produce zero twitches in ToF stimulation was longer in the middle-aged elderly group 
than the young elderly group (2.4 minutes and 1.48 minutes, P=0.009). One subject in the 
young elderly group was determined to have a relapse of NMB and was reintubated. 
 The CASP critical appraisal for this study is found in Appendix B, Table B-6. 
This study compared two geriatric populations without comparing an adult group aged 
<65 years. Overall, findings are congruent in other studies, that increased age of subjects 
is associated with increased time to recovery of ToFR 0.9 after administration of 
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sugammadex. While inhalational anesthetics were used and potentially a confounding 
variable, its impact may be lessened by the limited duration of surgery to less than two 
hours, less disparity of age when comparing two geriatric groups, and similar duration of 
anesthesia between the two groups. While sevoflurane was limited to end-tidal 
measurement of 1.5%, there was no discussion of age-adjusted dosing. 
 The cross-study analysis which details rocuronium and sugammadex dosage, 
results, and adverse events, can be found in Appendix D. Five out of six studies examined 
the use of sugammadex in reversal of rocuronium-induced NMB in both adult and 
geriatric age groups. Yazar et al. did not include non-geriatric subjects but stratified the 
aged population into young-elderly and middle-aged elderly in their study. There was 
also variation in the methodology among the six studies, such as level of NMB being 
reversed and dose of sugammadex administered.  Four studies (Kadoi et al., McDonaugh 
et al., Muramatsu et al., and Suzuki et al.) all generally found a longer recovery time for 
the geriatric population compared to non-geriatric population. Yazar et al., who did not 
include non-geriatric subjects, found that older age was associated with longer recovery 
time after sugammadex administration within the geriatric population. Shin et al., who 
investigated the sugammadex dose required for NMB recovery within two minutes, found 
that the geriatric group required a higher dose of sugammadex to achieve NMB recovery 
within targeted time compared to the non-geriatric group. Adverse events related to 
incomplete recovery or relapse of NMB were reported. Among all studies included, one 
subject experienced relapse of NMB and required reintubation (Yazar et al.). One subject 
experienced muscle weakness, but relapse of NMB was unable to be definitively ruled 
out beyond quantitative monitoring period (McDonaugh et al.). In the study by 
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Muramatsu et al., a negative change in ToFR was noted in eight subjects after receiving 
low dose sugammadex via infusion that was discontinued prior to NMB recovery to 
ToFR 0.9. Muramatsu et al. did not report any adverse events. 
Next, the summary and conclusions will be discussed. 
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Summary and Conclusions 
Sugammadex offers a novel approach to NMB reversal without the limitations 
and potential side effects associated with neostigmine. However, there is a lack of 
systematic reviews that examine the use of sugammadex among different age groups, 
specifically the geriatric population. The purpose of this systematic review was to 
determine if the geriatric population, compared to the adult population, requires an 
altered dose to reduce incidences of residual neuromuscular blockade during the 
postoperative period.  
A literature review which discussed definitions and measurement of recovery 
from NMB, incidence of incomplete recovery, and geriatric considerations was done. The 
theoretical framework outlined the use of PRISMA checklist and flow diagram to 
complete a systematic review. A search for studies meeting the inclusion criteria was 
completed using Ebscohost databases CINAHL, MEDLINE, and Academic Search 
Complete.  
An individual analysis was performed by completing a data collection table and a 
CASP checklist for each included study. The CASP checklist allowed for systematic 
appraisal of each study to identify limitations and assess the validity of an included 
study’s results. A cross-study analysis was then done to compare results and methods 
across all included studies. 
Overall, results of the cross-analysis show that the geriatric population, when 
receiving an equal weight-based dose of sugammadex, required a longer time to achieve 
NMB reversal than a younger adult population. Increased age was associated with longer 
recovery from NMB after sugammadex, even within the geriatric population. Adverse 
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events associated with residual NMB were infrequent amongst all included studies. In 
one study using low dose sugammadex infusion, a negative change in ToFR was 
observed in eight subjects but no adverse events were reported. It was not possible to 
assess if there was an increased risk of adverse events associated with residual NMB with 
the limited number of adverse events in the included studies for this systematic review. 
Several limitations were noted in this systematic review. First, the included 
studies had varied methodology in the dose of sugammadex, method of sugammadex 
administration, level of NMB that was reversed, and varied stratification of geriatric 
population. However, regardless of methodology, each study found that the group with 
increased age was associated with increased recovery time. Second, there were few 
reported adverse events that were associated with residual NMB amongst all included 
studies. Out of 340 subjects across all six included studies, one subject (65-74 years old) 
required reintubation postoperatively and one subject (≥75 years old) experienced muscle 
weakness but unable to definitively rule out residual NMB since the event occurred 
beyond the observation period of the study. A transient negative change in ToFR was 
observed in one subject <70 years old and seven subjects ≥70 years old following a low 
dose sugammadex infusion, but no adverse events were reported. With so few adverse 
events, it is not possible to assess if increased age was associated with increased adverse 
events from residual NMB. However, the infrequency of adverse events in this systematic 
review seems to agree with previous studies by Fourtier et al. (2015) and Saager et al. 
(2019) that found infrequent adverse events despite a high incidence of residual NMB. 
Third, the absence of randomized controlled trials limits the strength of concluding that 
increased age is a causative factor in prolonged recovery from NMB after sugammadex 
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administration. Several physiologic factors in the geriatric population discussed in the 
literature review can account for variations in response to NMB drugs and NMB reversal 
drugs compared to a younger adult population. Also, while all included studies 
standardized the dose of rocuronium and sugammadex according to weight, not all 
studies limited or standardized the use of inhalational anesthetic, used age-adjusted dose 
of inhalational anesthetic, or controlled for duration of surgery (which may expose the 
geriatric population to all anesthetic drugs for a longer duration). 
Next, the recommendations and implications for advanced nursing practice will 
be discussed. 
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Recommendations and Implications for Advanced Nursing Practice 
 Many surgical procedures require the use of NMB agents during anesthesia. The 
use of NMB agents also come with the need to reverse the effects of NMB. While 
acetylcholinesterase inhibitors have long been used to reverse NMB, they require 
anticholinergic drugs to manage side effects such as bradycardia, bronchoconstriction, 
and increased salivation. Sugammadex is a new class of NMB reversal agent showing 
some benefits over acetylcholinesterase inhibitors, but it is not without limitation and 
should be used with consideration to the patient’s specific needs. 
 The results of this systematic review show a correlation between increased age 
and increased time of NMB recovery after sugammadex administration. The prolonged 
recovery time following sugammadex bolus varied from less than 1 minute to more than 
2 minutes. The clinician should anticipate this response in the aged population and 
respond appropriately. Recovery from NMB should be confirmed using peripheral nerve 
stimulation, even after the administration of sugammadex. While residual NMB is 
associated with low dose sugammadex, incidence of residual NMB is rare if an 
appropriate dose of sugammadex is used relative to the depth of NMB to be reversed 
(McDonaugh et al., 2011). 
With a lack of randomized controlled trials and the limitations of this systematic 
review, there is insufficient evidence in this systematic review to support a 
recommendation to adjust the dose of sugammadex for the geriatric population. Further 
research is needed to investigate the underlying cause of prolonged NMB recovery in the 
geriatric population. Shin et al. (2015) suggested that tools to measure peripheral and 
muscle blood flow may help determine underlying cause. Suzuki et al. (2011) suggest 
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lower cardiac index may explain prolonged recovery time following sugammadex 
administration. Kadoi et al (2013) monitored cardiac output in their study but did not find 
a relationship between cardiac output and NMB recovery time after sugammadex. 
However, Kadoi et al. discuss that these results do not agree with other studies and 
suggest that a lack of inhalational agents (having vasodilating properties) and a release of 
catecholamines during ECT may explain their results.  
Certified Registered Nurse Anesthetists can play a vital role in education and 
expanding research needed to optimize anesthesia care for geriatric patients, a population 
that is rapidly growing and living longer. The geriatric population have many physiologic 
age-related changes which potentially alter responses to many aspects of anesthesia care. 
Ongoing research will be needed as anesthesia practice changes to ensure the geriatric 
population continues to receive optimal anesthesia care.  
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 Appendix A  
Section/ 
topic  # Checklist item  
Reported 
on page#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.   
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
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Appendix B 
Table B-1 
CASP Cohort Checklist 
Study 1. Kadoi, Y, Nishida, A., & Saito, S. (2013). Recovery time after sugammadex 
reversal of rocuronium-induced muscle relaxation for electroconvulsive therapy is 
independent of cardiac output in both young and elderly patients. Journal of ECT, 
29(1), 33-36. 
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue? X   
2. Was the cohort recruited in an acceptable way? X   
3. Was the exposure accurately measured to minimise 
bias? 
X   
4. Was the outcome accurately measured to minimise 
bias? 
X   
5a. Have the authors identified all important confounding 
factors?  
X   
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
X   
6a. Was the follow up of the subjects complete enough? X   
6b. Was the follow up of subjects long enough? X   
Section B. What are the results?    
7. What are the results of this study? Elderly group had longer 
recovery to ToFR 0.9 and 
not associated with CI. 
8. How precise are the results? Confidence intervals not 
provided. P values given.  
9. Do you believe the results? X   
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population? X   
11. Do the results of this study fit with other available 
evidence?  
Comment: ECT procedure necessitated reversal shortly 
after administration of rocuronium 
 X  
12. What are the implications of this study for practice? 
Comment: Large dose sugammadex (8mg·kg-1) used in a 
situation unique to ECT with small sample size. May not 
be able to generalize to other clinical scenarios. 
 X  
CI, cardiac index; ECT, electroconvulsive therapy; ToFR, train of four ratio  
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Table B-2 
CASP Cohort Checklist 
Study 2. McDonagh, D. L., Benedict, P. E., Kovac, A. L., Drover, D. R., Brister, N. 
W., Morte, J. B., & Monk, T. G. (2011). Efficacy, safety, and pharmacokinetics of 
sugammadex for the reversal of rocuronium-induced neuromuscular blockade in 
elderly patients. Anesthesiology, 114(2), 318-329.  
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue? X   
2. Was the cohort recruited in an acceptable way? X   
3. Was the exposure accurately measured to minimise 
bias? 
X   
4. Was the outcome accurately measured to minimise 
bias? 
X   
5a. Have the authors identified all important confounding 
factors?  
Comment: Authors did not specifically mention 
temperature control of ToFR monitoring site. Only core 
temperature control mentioned. Age-adjusted dosing of 
volatile anesthetics not discussed. 
 X  
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
X   
6a. Was the follow up of the subjects complete enough? X   
6b. Was the follow up of subjects long enough? X   
Section B. What are the results?    
7. What are the results of this study? Old-elderly (≥75 years old) and elderly 
(65-74 years old) groups had longer 
recovery time to ToFR 0.9 after 
sugammadex compared to adult (18-64 
years old) group 
8. How precise are the results? Confidence intervals and p-values given. 
9. Do you believe the results? X   
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population? X   
11. Do the results of this study fit with other available 
evidence? 
X   
12. What are the implications of this study for practice? 
Comment: Larger sample size in multiple sites increases 
generalizability of results. 
X   
ToFR, Train of Four Ratio  
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Table B-3 
CASP Cohort Checklist 
Study 3. Muramatsu, T., Isono, S., Ishikawa, T., Nozaki-Taguchi, N., Okazaki, J., 
Kitamura, Y., Murakami, N., & Sato, Y. (2018). Differences in recovery from 
rocuronium-induced deep paralysis in response to small doses of sugammadex between 
elderly and nonelderly patients. Anesthesiology, 129, 901-911. 
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue? X   
2. Was the cohort recruited in an acceptable way? X   
3. Was the exposure accurately measured to minimise bias? X   
4. Was the outcome accurately measured to minimise bias? X   
5a. Have the authors identified all important confounding 
factors?  
X   
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
X   
6a. Was the follow up of the subjects complete enough? X   
6b. Was the follow up of subjects long enough? 
Comment: No discussion of PACU monitoring for adverse 
events. Additional sugammadex after observation ended 
and prior to subject entering PACU likely reduced risk of 
adverse events and done prudently to avoid risk of 
insufficient sugammadex dosing inherent to study design. 
 X  
Section B. What are the results?    
7. What are the results of this study? Increase incidence of relapse and slower 
recovery of NMB after low dose 
sugammadex in elderly. 
8. How precise are the results? p-values and confidence intervals given. 
9. Do you believe the results? X   
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population? X   
11. Do the results of this study fit with other available 
evidence? 
Comment: Use of sugammadex infusion followed by bolus 
is not usual clinical practice and may not accurately reflect 
outcomes in clinical practice. 
 X  
12. What are the implications of this study for practice? 
Comment: Supportive evidence but altered sugammadex 
administration may impact generalizability of results. 
 X  
NMB, neuromuscular blockade; PACU, postanesthesia care unit  
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Table B-4 
CASP Cohort Checklist 
Study 4. Shin, S., Han, D. W., Lee, H S., Song, M. K., Jun, E., & Kim, S. Y. (2016). 
Elderly patients require higher doses of sugammadex for rapid recovery from deep 
neuromuscular block. Basic & Clinical Pharmacology & Toxicology, 118, 462-467. 
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue? X   
2. Was the cohort recruited in an acceptable way? X   
3. Was the exposure accurately measured to minimise 
bias? 
X   
4. Was the outcome accurately measured to minimise 
bias? 
X   
5a. Have the authors identified all important confounding 
factors?  
X   
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
X   
6a. Was the follow up of the subjects complete enough? X   
6b. Was the follow up of subjects long enough? X   
Section B. What are the results?    
7. What are the results of this study? Difference between adult (20-40 years 
old) and elderly (≥70 years old) ED50 and 
ED95 of sugammadex for rapid NMB 
recovery within 2 min was statistically 
significant. 
8. How precise are the results? p-values and confidence intervals given. 
9. Do you believe the results? X   
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population? X   
11. Do the results of this study fit with other available 
evidence? 
X   
12. What are the implications of this study for practice? 
Comment: Elderly group may require a higher 
sugammadex dose to achieve same recovery time as 
Adult group.  
X   
NMB, neuromuscular blockade 
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Table B-5 
CASP Cohort Checklist 
Study 5. Suzuki, T., Kitajima, O., Ueda, K., Kondo, Y., Kato, J., & Ogawa, S. (2011). 
Reversibility of rocuronium-induced profound neuromuscular block with sugammadex 
in younger and older patients. British Journal of Anaesthesia, 106(6), 823-826. 
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue? X   
2. Was the cohort recruited in an acceptable way? X   
3. Was the exposure accurately measured to minimise 
bias? 
X   
4. Was the outcome accurately measured to minimise 
bias? 
X   
5a. Have the authors identified all important confounding 
factors?  
Comment: No age-adjusted dose of sevoflurane discussed 
but limited to 1%-1.5%. Unknown if elderly group 
overrepresented with ASA Physical Status 3 subjects. 
 X  
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
X   
6a. Was the follow up of the subjects complete enough? X   
6b. Was the follow up of subjects long enough? X   
Section B. What are the results?    
7. What are the results of this study? Longer recovery from PTC 1-2 to ToFR 
0.9 in elderly (≥70 years old) compared to 
adult (20-50 years old). 
8. How precise are the results? p-values and data ranges given without 
confidence intervals. 
9. Do you believe the results? X   
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population? 
Comment: Sample was only women. No male subjects. 
Limited demographic information given. 
 X  
11. Do the results of this study fit with other available 
evidence? 
X   
12. What are the implications of this study for practice? 
Comment: Increased age correlated with increased 
recovery time from deep NMB. 
X   
ASA, American Society of Anesthesiologists; NMB, neuromuscular blockade; PTC, 
post-tetanic count; ToFR, Train of Four Ratio  
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Table B-6 
CASP Cohort Checklist 
Study 6. Yazar, E., Yilmaz, C., Bilgin, H., Karasu, D., Bayraktar, S., Apaydin, Y., & 
Sayan, H. E. (2016). A comparison of the effect of sugammadex on the recovery period 
and postoperative residual block in young elderly and middle-aged elderly patients. 
Balkan Medical Journal, 33, 181-187. 
Section A. Are the results of the study valid? Yes  Can’t Tell No 
1. Did the study address a clearly focused issue? X   
2. Was the cohort recruited in an acceptable way? X   
3. Was the exposure accurately measured to minimise 
bias? 
X   
4. Was the outcome accurately measured to minimise 
bias? 
X   
5a. Have the authors identified all important confounding 
factors?  
Comment: Sevoflurane was limited to 1.5% but age-
adjusted dose of inhalational agent not discussed. This 
variable may have less impact due to exclusion of adults 
<65 years old and less age disparity among subjects. 
X   
5b. Have the taken account of the confounding factors in 
the design and/or analysis? 
X   
6a. Was the follow up of the subjects complete enough? X   
6b. Was the follow up of subjects long enough? X   
Section B. What are the results?    
7. What are the results of this study? Time to recovery of ToFR was longer 
with group 2 (≥75 years old) than group 1 
(65-74 years old). 
8. How precise are the results? p-values given with medians and ranges. 
No standard deviation or confidence 
intervals with time to recovery results. 
9. Do you believe the results? X   
Section C. Will the results help locally? Yes Can’t Tell No 
10. Can the results be applied to the local population? X   
11. Do the results of this study fit with other available 
evidence? 
X   
12. What are the implications of this study for practice? 
Comment: Even within the geriatric group, older age is 
associated with longer recovery time. 
X   
ToFR, Train of Four Ratio 
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Appendix C 
Table C-1 
Data Collection Table 
Study 1. Kadoi, Y, Nishida, A., & Saito, S. (2013). Recovery time after sugammadex reversal of rocuronium-induced muscle 
relaxation for electroconvulsive therapy is independent of cardiac output in both young and elderly patients. Journal of ECT, 29(1), 
33-36. 
Purpose Site/Sample Method Results Limitations 
1. To compare recovery 
times from rocuronium-
induced NMB using 
sugammadex between 
young and elderly 
groups undergoing 
ECT. 
 
2. To investigate the 
existence of a 
correlation between 
cardiac index and the 
reversibility of 
rocuronium-induced 
NMB using 
sugammadex after ECT. 
Site not discussed. 
 
17 subjects. Elderly 
group (n=9, age ≥70 
years) and young group 
(n=8, age ≤50 years). 
 
ASA PS not discussed. 
 
Exclusion: patients with 
renal, hepatic, 
cardiovascular, 
neuromuscular disease, 
or BMI >35kg·m-2 
General anesthesia 
induced with propofol 1 
mg·kg-1 and rocuronium 
0.6 mg·kg-1. ECT 
initiated after ToF count 
of zero. Sugammadex 8 
mg·kg-1 given 
immediately after 
seizure cessation. 
 
ToF SX watch used for 
NMB monitoring. 
Young Group: Time to 
ToFR 0.9 after 
sugammadex was 
403±37 seconds. 
 
Elderly Group: Time to 
ToFR 0.9 after 
sugammadex was 
443±36 seconds 
(P=0.04) 
 
 
A large dose of 
sugammadex was given 
immediately after 
cessation of seizure 
activity, during an 
ongoing state of deep 
NMB.  
 
Recovery times after 
sugammadex was 
longer in this study 
compared to other 
reports, with may have 
been influenced by 
timing of rocuronium, 
ECT, sugammadex, and 
overall physical health 
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status during chronic 
psychiatric illness. 
ASA PS, American Society of Anesthesiologists physical status; BMI, body mass index; ECT, electroconvulsive therapy; NMB, 
neuromuscular blockade; ToF, train of four; ToFR, train of four ratio  
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Table C-2 
Data Collection Table 
Study 2. McDonagh, D. L., Benedict, P. E., Kovac, A. L., Drover, D. R., Brister, N. W., Morte, J. B., & Monk, T. G. (2011). Efficacy, 
safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. 
Anesthesiology, 114(2), 318-329. 
Purpose Site/Sample Method Results Limitations 
To assess the impact of 
age (≥65 years old) on 
efficacy, safety, and 
pharmacokinetics of 
sugammadex for 
reversal from moderate 
rocuronium-induced 
NMB 
14 medical centers in 
the United States. 
 
150 patients stratified 
into 3 groups: adult (18-
64 years old), elderly 
(65-74 years old), and 
old-elderly (≥75 years 
old). 
 
ASA PS 1-3 undergoing 
elective supine surgery 
under general anesthesia 
requiring muscle 
relaxation. 
 
Exclusion: 
neuromuscular disorder, 
anticipated difficult 
Rocuronium 0.6mg·kg-1 
initially followed by 
maintenance doses of 
0.15 mg·kg-1 as needed 
upon reappearance of 
second twitch in ToF. 
Sugammadex 2 mg·kg-1 
given at end of surgery 
upon reappearance of 
second twitch in ToF. 
 
ToF Watch SX used for 
NMB monitoring. 
Adult group (n=45) 
mean time to recover 
ToFR 0.9 was 2.3 min. 
 
Elderly group (n=57) 
mean time to recover 
ToFR 0.9 was 2.7 min. 
 
Old-elderly (n=35) 
mean time to recover 
ToFR 0.9 was 3.7 min. 
P value 0.017 
 
Data from 13 subjects 
were considered 
unreliable or 
unavailable. Results 
with these subjects were 
reported separately and 
No masking or 
randomization.  
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intubation due to 
anatomy, creatinine 
clearance ≤30ml/min, 
family or personal 
history of malignant 
hyperthermia, known 
allergy to medication 
used in general 
anesthesia, or receiving 
medications known to 
interfere with NMB 
agents. 
by imputing in the 
above data using 95th 
percentile information.  
NMB, neuromuscular blockade; ToFR, train of four ratio 
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Table C-3 
Data Collection Table 
Study 3. Muramatsu, T., Isono, S., Ishikawa, T., Nozaki-Taguchi, N., Okazaki, J., Kitamura, Y., Murakami, N., & Sato, Y. (2018). 
Differences in recovery from rocuronium-induced deep paralysis in response to small doses of sugammadex between elderly and 
nonelderly patients. Anesthesiology, 129, 901-911. 
Purpose Site/Sample Method Results Limitations 
To test hypothesis that 
recovery from deep 
NMB with low dose 
sugammadex is slower 
in elderly patients than 
in nonelderly patients, 
and also a higher 
incidence of 
recurarization in 
elderly. 
Single center. 
 
Nonelderly group (<70 
years old, n=20) and 
elderly group (≥70 
years old, n=20) 
undergoing surgery with 
general anesthesia using 
total intravenous 
anesthetic. 
 
Exclusion: severe 
comorbidities, high risk 
aspiration, allergy to 
NMB agents, propofol, 
or sugammadex, 
surgery that is 
undesirable for 
administration of 
Nonrandomized 
observational study. 
 
Rocuronium 0.6mg·kg-1 
with induction. After 
spontaneous recovery to 
ToFR > 0.5, rocuronium 
0.4 mg·kg-1 given with 
additional dose 0.2 
mg·kg-1 if needed to 
attain PTC 2-10. Once 
PTC range achieved, 
sugammadex infusion 
50 mcg·kg-1·min until 
ToF count of 3 achieved 
and sugammadex 
infusion stopped. 
 
ToF Watch SXTM 
Spontaneous recovery 
time to ToF count 1 
after initial rocuronium: 
nonelderly group 30.2 
min, elderly group 45.4 
min (P value 0.016). 
 
Recovery time to ToF 
count 3 after initiation 
of sugammadex 
infusion: nonelderly 
group 11.7 min, elderly 
group 15.3 min (P value 
0.018). 
 
Slower rate of late-
phase recovery from 
NMB in Elderly group 
Use of sugammadex 
infusion experimentally 
does not reflect actual 
practice and results may 
not reflect actual 
clinical incidences. 
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rocuronium or 
sugammadex, and 
patients taking 
medications with known 
interaction of 
rocuronium or 
sugammadex. 
(0.6%/min vs 1.7%/min, 
P=0.006) 
NMB, neuromuscular blockade; PTC, post-tetanic count; ToF, train of four; ToFR, train of four ratio 
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Table C-4 
Data Collection Table 
Study 4. Shin, S., Han, D. W., Lee, H S., Song, M. K., Jun, E., & Kim, S. Y. (2016). Elderly patients require higher doses of 
sugammadex for rapid recovery from deep neuromuscular block. Basic & Clinical Pharmacology & Toxicology, 118, 462-467. 
Purpose Site/Sample Method Results Limitations 
To compare the dose of 
sugammadex needed in 
elderly and young 
adults to recover from 
deep NMB within 2 
min. 
Single center. 
 
44 subjects: young adult 
group (n=22, age 
between 20 and 40 
years old) and elderly 
adult group (n=22, ≥70 
years old) undergoing 
elective ENT surgery 
under general anesthesia 
in supine position. ASA 
PS 1-2. 
 
Exclusion: anticipated 
difficult airway, history 
of malignant 
hyperthermia or 
neuromuscular disease, 
significant renal or 
hepatic dysfunction, 
Initial dose rocuronium 
0.6 mg·kg-1 with 
maintenance dose of 0.2 
mg·kg-1 to maintain 
target depth of NMB at 
1 or 2 PTC until end of 
operation. First patient 
received sugammadex 4 
mg·kg-1 with dose for 
subsequent 
increased/decreased 0.5 
mg·kg-1 based on 
previous dose 
failure/success to 
recover ToFR ≥0.9 
within 2 min. 
 
ToF Watch SX 
 
ED50 and ED95 of 
sugammadex in young 
adult group is 3.3 
mg·kg-1 and 4.4mg·kg-1, 
respectively. ED50 and 
ED95 of sugammadex in 
elderly adult group is 
4.5 mg·kg-1 and 5.4 
mg·kg-1, respectively. 
 
Determined statistically 
significant by non-
overlapping confidence 
interval method. 
Unable to determine 
cause of delayed 
recovery in elderly. 
 
Comorbidity differences 
between the two groups 
may be a confounding 
factor. 
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allergy to opioids, 
muscle relaxants, or 
general anesthetics, 
pregnant, breastfeeding, 
using medications with 
known interaction with 
NMB agents, and BMI 
<17 kg·m2 or ≥30 
kg·m2. 
Sugammadex dose 
prepared into 5 mL 
unmarked syringe by 
nurse unaffiliated with 
study. 
ASA PS, American Society of Anesthesiologists Physical Status; BMI, body mass index; ED50, effective dose for 50% of subjects 
(83% confidence interval); ED95, effective dose for 95% of subjects (confidence interval 95%); NMB, neuromuscular blockade; PTC, 
post-tetanic count; ToF, train of four; ToFR, train of four ratio 
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Table C-5 
Data Collection Table 
Study 5. Suzuki, T., Kitajima, O., Ueda, K., Kondo, Y., Kato, J., & Ogawa, S. (2011). Reversibility of rocuronium-induced profound 
neuromuscular block with sugammadex in younger and older patients. British Journal of Anaesthesia, 106(6), 823-826. 
Purpose Site/Sample Method Results Limitations 
To compare the 
reversibility of profound 
rocuronium-induced 
neuromuscular block 
with sugammadex 
between younger and 
older patients. 
Younger adult group 
(n=15, age between 20 
and 50 years) and Older 
adult group (n=15, ≥70 
years old) undergoing 
gynecological surgery 
under general 
anesthesia. ASA PS 1-3, 
patients without 
neuromuscular, renal, or 
hepatic disorders, or 
taking medications with 
known interaction with 
NMB agents. 
 
Exclusion: BMI ≥25 or 
BMI ≤18.5. 
Initial rocuronium dose 
1 mg·kg-1 with 
subsequent doses of 
0.02 mg·kg-1 whenever 
a PTC of 1 or 2 was 
observed. Sugammadex 
4 mg·kg-1 given at end 
of surgery after 
spontaneous recover to 
PTC 1-2 since previous 
rocuronium dose. 
 
ToF watch SX 
Time to recovery of 
ToFR 0.9 after 
sugammadex dose: 
younger adult group 1.3 
min (SD 0.3, 0.8-2.0 
min), older adult group 
3.6 min (SD 0.7, 2.4-4.5 
min). P value <0.0001. 
 
ToFR data was 
normalized. 
Only female subjects. 
May limit 
generalizability to other 
populations. 
 
Use of volatile 
anesthetic in general 
anesthesia may have 
enhanced NMB effect. 
Dose was not age-
adjusted and older adult 
group may have 
received greater dose of 
sevoflurane. Longer 
duration of surgery for 
older adult group, which 
increases duration of 
sevoflurane exposure. 
ASA PS, American Society of Anesthesiologists physical status; BMI, body mass index; NMB, neuromuscular blockade; PTC, post-
tetanic count; SD, standard deviation; ToF, train of four; ToFR, train of four ratio  
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Table C-6 
Data Collection Table 
Study 6. Yazar, E., Yilmaz, C., Bilgin, H., Karasu, D., Bayraktar, S., Apaydin, Y., & Sayan, H. E. (2016). A comparison of the effect 
of sugammadex on the recovery period and postoperative residual block in young elderly and middle-aged elderly patients. Balkan 
Medical Journal, 33, 181-187. 
Purpose Site/Sample Method Results Limitations 
To investigate the 
effects of sugammadex 
on the duration of 
recovery from NMB 
agents and relapse of 
NMB effect in young 
elderly and middle-aged 
elderly groups. 
Young elderly (n=30, 
age 65-74 years) and 
middle-aged elderly 
(n=29, age ≥75 years) 
undergoing 
laparoscopic 
cholecystectomy.  
 
ASA PS 1-3. 
 
Exclusion: renal or 
hepatic failure, 
neuromuscular disease, 
history of malignant 
hyperthermia, BMI >30. 
Patients with failed 
laparoscopic 
intervention, surgery 
duration >2 hours, or 
Initial dose rocuronium 
0.6 mg·kg-1 with 
subsequent rocuronium 
doses 0.15 mg·kg-1 
when ToF count 2 or 
more. Sugammadex 2 
mg·kg-1 given when 
ToF count was 2 and 
surgery is finished. 
Recovery time to ToFR 
0.9 and incidences of 
ToFR returning to <0.9 
postoperatively 
recorded. 
 
ToF Watch SX 
Young elderly group 
recovery to ToFR 0.9 
was 3.27 min. Middle-
aged elderly group 
recovery to ToFR 0.9 
was 5.5 min (P value 
<0.001). 
Inhalational anesthetic 
used in this study, 
which may enhance 
NMB agent effect. 
Controlling inhalation 
agent to end-tidal 1.5% 
sevoflurane between 
groups attempted to 
limit this confounding 
variable, as did the 
limitation of surgery to 
less than 2 hours also. 
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admitted to ICU 
intubated were also 
excluded.  
ASA PS, American Society of Anesthesiologists; BMI, body mass index; NMB, neuromuscular blockade; ToF, train of four; ToFR, 
train of four ratio 
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Appendix D 
Cross-Study Analysis 
Study NMB dose Sugammadex dose Geriatric time to 
recovery 
Adult time to 
recovery 
Adverse Events 
1 Rocuronium 0.6 
mg·kg-1 
8 mg·kg-1 with ToF 
being zero and 
immediately after 
seizure stopped 
≥70 years old: 
443 ±36 sec (mean ± 
SD) 
≤50 years old: 
403 ± 37 sec (mean ± 
SD) 
No postoperative events 
related to recurarization or 
respiratory events reported. 
2 Rocuronium 0.6 
mg·kg-1 with 
maintenance dose 
of 0.15 mg·kg-1 
as needed with 
reappearance of 
second twitch in 
ToF. 
2 mg·kg-1 upon 
reappearance of 
second twitch in 
ToF at end of 
surgery. 
65-74 years old: 
time to recover ToFR 
0.9 was 2.7 min (mean, 
SD 1.4 min). 
 
≥75 years old: 
time to recover ToFR 
0.9 was 3.7 min (mean, 
SD 1.6 min).  
 
all subjects ≥65 years 
old: time to recover 
ToFR 0.9 was 3.1 min 
(mean, SD 1.6 min). 
P value 0.017 
18-64 years old: 
time to recover ToFR 
0.9 was 2.3 min (mean, 
SD 1.0 min). 
 
Two subjects in 65-74 years 
old group had adverse events 
that investigators felt may be 
related to sugammadex. One 
experienced tachycardia, 
pyrexia, dizziness, and 
oliguria. The other 
experienced procedural 
hypotension.  
One subject in Old-elderly 
group reported mild muscle 
weakness, but unable to 
definitively rule out relapse 
of NMB as quantitative 
monitoring had ceased by 
this point. 
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3 Rocuronium 
0.6mg·kg-1 with 
induction. After 
spontaneous 
recovery to ToFR 
> 0.5, 
rocuronium 0.4 
mg·kg-1 given 
with additional 
dose 0.2 mg·kg-1 
if needed to attain 
PTC 2-10. 
Once PTC range 2-
10 achieved, 
sugammadex 
infusion 50 
mcg/kg/min until 
ToF count of 3 
achieved and 
sugammadex 
infusion stopped. 
≥70 years old: 
spontaneous recovery to 
ToF count 1 after initial 
rocuronium was 45.4 
minutes. 
 
Recovery to ToF count 
of 3 after sugammadex 
infusion was 15.3 
minutes. 
<70 years old: 
spontaneous recovery to 
ToF count 1 after initial 
rocuronium was 30.2 
minutes. 
 
Recovery to ToF count 
3 after sugammadex 
infusion was 11.7 
minutes. 
A transient negative change 
in ToFR recovery was noted 
in 1 subject <70 years old 
and 7 subjects ≥70 years old. 
4 Rocuronium 0.6 
mg·kg-1 with 
maintenance dose 
of 0.2 mg·kg-1 to 
maintain target 
depth of NMB at 
1 or 2 PTC 
First patient 
received 4 mg·kg-1, 
with dose for 
subsequent subject 
increased/decreased 
0.5 mg·kg-1 based 
on previous subject 
failure/success to 
recover ToFR ≥0.9 
within 2 min. 
≥70 years old: 
ED50 and ED95 of 
sugammadex is 4.5 
mg·kg-1 and 5.4 mg·kg-
1, respectively. 
 
20-40 years old: 
ED50 and ED95 of 
sugammadex is 3.3 
mg·kg-1 and 4.4 mg·kg-
1, respectively. 
 
No postoperative events 
related to recurarization or 
respiratory events reported. 
5 Rocuronium dose 
1 mg·kg-1 with 
subsequent doses 
of 0.02 mg·kg-1 
whenever a PTC 
4 mg·kg-1 given at 
end of surgery after 
spontaneous 
recover to PTC 1-2 
≥70 years old: 
Time to recovery of 
ToFR 0.9 after 
sugammadex was 3.6 
20-50 years old: 
Time to recovery of 
ToFR 0.9 after 
sugammadex was 1.3 
No postoperative events 
related to recurarization or 
respiratory events reported. 
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of 1 or 2 was 
observed. 
since previous 
rocuronium dose. 
min (SD 0.7, 2.4-4.5 
min). 
min (SD 0.3 min, 0.8-
2.0 min). 
6 Rocuronium 0.6 
mg·kg-1 with 
subsequent 
rocuronium doses 
0.15 mg·kg-1 with 
ToF count 2 or 
more. 
2 mg·kg-1 given 
when ToF count 
was 2 and surgery 
is finished. 
65-74 years old: 
recovery to ToFR 0.9 
was 3.27 min (median, 
range 1.41-5.37 min). 
 
≥75 years old: 
recovery to ToFR 0.9 
was 5.5 min (median, 
2.47-9.54 min).  
No subjects <65 years 
old were included in 
this study. 
Postoperative recurarization 
was reported in 1 subject in 
the 65-74 years old group 
with subsequent reintubation 
performed. 
 
